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Abstract 1 
 2 
 3 
Adults presenting with sporadic hypophosphatemia and elevations in circulating fibroblast growth 4 
factor-23 (FGF23) concentrations are usually investigated for an acquired disorder of FGF23 excess 5 
such as tumor induced osteomalacia (TIO). However, in some cases the underlying tumor is not 6 
detected, and such patients may harbor other causes of FGF23 excess. Indeed, coding-region and 7 
3’UTR mutations of phosphate-regulating neutral endopeptidase (PHEX), which encodes a cell-8 
surface protein that regulates circulating FGF23 concentrations, can lead to alterations in phosphate 9 
homeostasis, which are not detected until adulthood. Here, we report an adult female who presented 10 
with hypophosphatemic osteomalacia and raised serum FGF23 concentrations. The patient and her 11 
parents, who were her only first-degree relatives, had no history of rickets. The patient was thus 12 
suspected of having TIO. However, no tumor had been identified following extensive localization 13 
studies. Mutational analysis of the PHEX coding-region and 3’UTR was undertaken, and this revealed 14 
the patient to be heterozygous for a novel germline PHEX mutation (c.2158G>T; p.Ala720Ser). In 15 
vitro studies involving the expression of WT and mutant PHEX proteins in HEK293 cells 16 
demonstrated the Ala720Ser mutation to impair trafficking of PHEX, with <20% of the mutant 17 
protein being expressed at the cell surface, compared to >80% cell surface expression for WT PHEX 18 
(p<0.05). Thus, our studies have identified a pathogenic PHEX mutation in a sporadic case of adult-19 
onset hypophosphatemic osteomalacia, and these findings highlight a role for PHEX gene analysis in 20 
some cases of suspected TIO, particularly when no tumor has been identified.  21 
 22 
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1. Introduction 1 
 2 
The circulating concentration of phosphate is regulated by fibroblast growth factor-23 (FGF23), 3 
which is an osteocyte-derived hormone that influences proximal renal tubular phosphate reabsorption 4 
and the renal synthesis of 1,25-dihydroxyvitamin D (1). Primary disorders of FGF23 excess are 5 
characterized by renal tubular phosphate wasting and low serum 1,25-dihydroxyvitamin D 6 
concentrations, which lead to hypophosphatemia and impaired skeletal mineralization (1, 2). The 7 
most common inherited cause of FGF23 excess is X-linked hypophosphatemia (XLH; OMIM 8 
#307800), which has a prevalence of 1:20,000 (3), and is caused by loss-of-function mutations 9 
affecting the PHEX gene on chromosome Xp22.1 (4-7). PHEX encodes the phosphate-regulating 10 
neutral endopeptidase, which is a cell-surface protein expressed in osteocytes, osteoblasts and 11 
odontoblasts; and considered to play a role in inhibiting FGF23 synthesis (1). XLH is in general a 12 
highly penetrant X-linked dominant disorder characterized by childhood rickets, which is 13 
unresponsive to physiological doses of vitamin D, and occurs in association with growth retardation 14 
and dental abnormalities (5, 8). However, XLH can also mimic a sporadic or X-linked recessive form 15 
of rickets, which is characterized by a mild clinical phenotype, and caused by a mutation within the 16 
PHEX 3’-UTR region (9). In contrast to XLH, which generally manifests in the second year of life 17 
when affected individuals begin weight-bearing, patients presenting in adulthood with 18 
hypophosphatemia and elevated serum FGF-23 concentrations, in the absence of any family history of 19 
rickets, are usually investigated for an underlying acquired cause such as tumor induced osteomalacia 20 
(TIO) (10). This paraneoplastic disorder is most commonly caused by the ectopic secretion of FGF23 21 
from benign mesenchymal tumors (11, 12). The diagnosis of TIO is often difficult as the causative 22 
mesenchymal tumors are generally small and occur in any soft tissue or bone (13). Indeed, despite 23 
extensive tumor localization studies, which may span several years and involve a range of imaging 24 
modalities such as whole body MRI, octreotide scintigraphy and 18fluorodeoxyglucose PET/CT 25 
(FDG-PET/CT) (14), the underlying cause of the FGF23 excess is often not established. Here, we 26 
report a previously well patient with no known family history of rickets, who presented with 27 
hypophosphatemic osteomalacia and raised serum FGF23 concentrations in adulthood. She was 28 
 4 
suspected as having TIO, but no tumor was detected. However, mutational analysis identified a novel 1 
germline loss-of-function PHEX mutation, and these findings suggest that PHEX mutations may 2 
account for some cases of sporadic adult-onset hypophosphatemic osteomalacia. 3 
 4 
2. Case Report 5 
 6 
A previously well 43-year-old woman presented with widespread psoriasis in association with a 12-7 
month history of pain and stiffness affecting the lumbar back, hips and feet; and swelling of the 8 
metacarpophalangeal joints. She was not on any regular medications, did not take any vitamins or 9 
tonics, and had not altered her diet. She was diagnosed with a late-onset form of psoriatic arthritis 10 
(PsA) (presenting at >40 years), which accounts for ~30% of all PsA cases (15). She had a 11 
persistently raised erythrocyte sedimentation rate (ESR), ranging from 26-81 mm/hr (normal 2-19 12 
mm/hr), which is observed in ~50% of PsA patients (16). However, her symptoms did not improve 13 
following treatment with methotrexate. Plain radiography identified Looser zones affecting the 14 
femora (Fig. 1A), and she was assumed to also have vitamin D deficient osteomalacia, and 15 
commenced on ergocalciferol 250 micrograms weekly, However, her symptoms persisted, and serum 16 
biochemistry, which was measured on a random (non-fasting) sample, following three months of 17 
treatment with ergocalciferol revealed a low phosphate of 0.43 mmol/L (normal 0.70-1.40 mmol/L), 18 
normal concentrations of albumin-adjusted calcium and creatinine, borderline elevation of alkaline 19 
phosphatase (ALP) activity, adequate 25-hydroxyvitamin D of 72.4 nmol/L (29.0 ng/mL) and raised 20 
parathyroid hormone concentration (Table 1). Tubular maximum of phosphate/glomerular filtration 21 
rate (TmP/GFR) was low at 0.40 mmol/L (normal 0.80-1.35 mmol/L), consistent with a renal tubular 22 
phosphate loss. No alterations in serum electrolytes or urate concentrations were noted (Table 1). 23 
Moreover, urinary glucose was not detected, and the urinary concentrations of amino acids and retinol 24 
binding protein were not elevated, thus indicating that the patient did not have a generalised 25 
disturbance of proximal renal tubular function. Serum 1,25-dihydroxyvitamin D was inappropriately 26 
normal, given the hypophosphatemia; at 98 pmol/L (normal 43-144 pmol/L).  Serum FGF23, which 27 
was measured using the human C-terminal FGF23 ELISA (Immutopics) (17), was elevated at 779 28 
 5 
RU/mL (normal <100 RU/mL). These findings were consistent with FGF23-mediated 1 
hypophosphatemia. She had no childhood history of rickets, and the onset of her hypophosphatemia 2 
was not known, as serum biochemical profiling had not been previously undertaken. Moreover, it was 3 
uncertain whether there was a family history of rickets as she had no children or siblings. However, 4 
her parents were not known to be of short stature or affected by any musculoskeletal disorders. She 5 
had a history of dental abscesses, which were attributed to dental trauma as a child. Her height was 6 
150 cm (4 feet and 11 inches), which is within the normal range for women of her ethnicity (Middle 7 
Eastern origin) and corresponds to the 12th height centile. No disproportionate lower limb shortening 8 
was noted, and the upper and lower segment heights were 70cm and 80cm, respectively. No frontal 9 
bossing or other skeletal deformities were detected on examination. Mild enthesopathic changes 10 
affecting the ischial tuberosities, and an incidental finding of L5 spina bifida, were noted on a review 11 
of her plain radiographs (Fig. 1A). No abnormalities were detected on technetium 99m skeletal 12 
scintigraphy. She had no known acquired causes of FGF23 excess, such as being treated with iron 13 
infusions or having undergone a renal transplant (18, 19). Investigations for TIO, which included 14 
whole body MRI, octreotide scintigraphy and FDG-PET/CT did not detect an underlying tumor. She 15 
was commenced on oral phosphate (500 mg elemental phosphorus 2-3 times daily) and alfacalcidol 16 
250 ng daily, which improved the hypophosphatemia and normalised the ALP activity (Fig. 1B). 17 
However, she has remained symptomatic and her serum C-terminal FGF23 concentrations have been 18 
persistently elevated (Fig. 1B). This patient has been assessed over a period of eight years with serial 19 
imaging studies for presumed TIO, and no causative tumor has been identified. 20 
 21 
  22 
 6 
3. Methods 1 
 2 
3.1 Genetic analysis 3 
All genetic analyses were performed by the Department of Molecular Genetics at the Royal Devon 4 
and Exeter Hospital, UK. PCR and Sanger sequence analysis of all 22 exons of the PHEX gene was 5 
performed using leukocyte DNA. PCR primer sequences are available on request. PHEX gene dosage 6 
analysis was assessed by multiple ligation-dependent probe amplification (MLPA) using MRC 7 
Holland kit P2223-B1. Subsequent analysis of the DMP1, ENPP1, FGF23, PHEX and SLC34A3 8 
genes was undertaken by targeted next generation sequencing (Agilent custom capture v6/Illumina 9 
NextSeq500). All the coding regions and exon/intron boundaries (50 bp upstream to 10 bp 10 
downstream of each exon) were analysed for these five genes and also included the 3’UTR region of 11 
the PHEX gene for the detection of the reported c.*231A>G mutation (9). Publicly accessible 12 
databases including the Exome Variant Server (EVS) (http://evs.gs.washington.edu/EVS/) and the 13 
Exome Aggregation Consortium (EXAC) (http://exac.broadinstitute.org/), PHEX mutation database 14 
'PHEXdb' (http://www.phexdb.mcgill.ca/) and HGMD Pro >(https://portal.biobase-15 
international.com/hgmd/pro/start.php) were examined for the presence of any detected sequence 16 
variants. PHEX ortholog protein sequences were aligned using ClustalOmega 17 
(http://www.ebi.ac.uk/Tools/msa/clustalo/) (20).  18 
 19 
3.2 Cellular analysis of PHEX protein expression 20 
HEK293 cells were cultured in DMEM (Sigma) supplemented with 10% FBS (Invitrogen). Cells were 21 
split into 12-well plates, and transfected using Lipofectamine 2000 (Invitrogen) and vectors encoding 22 
either the full-length wild-type (WT) human PHEX (Source Bioscience; clone accession: KJ891794) 23 
or mutant PHEX (GeneArt, Invitrogen; mutation: c.2158G>T) or an empty pCS3 vector, as described 24 
(21, 22). Cells were lysed for western blotting or fixed for immunostaining 48h following 25 
transfections. HEK293 cells were lysed using RIPA buffer and denatured in Laemmli sample buffer 26 
(21). Protein separation and western blot were performed, as described (22). An anti-PHEX rabbit 27 
polyclonal antibody (Abcam, ab96072) was used at 1:500 dilution. Secondary HRP-conjugated 28 
 7 
antibody (anti-rabbit; Cell Signalling) was used at 1:2000 dilution. Immune complexes were 1 
visualised by chemiluminescence using ECL kit (Thermo Fisher Scientific). Ponceau S staining (Po-2 
S, Sigma Co,) was used to visualise the loaded protein. HEK293 cells were fixed in 4% 3 
paraformaldehyde in PBS, and immunostaining performed, as described (22). To assess for PHEX 4 
and endoplasmic reticulum (ER) co-immunostaining, cells were permeabilised with 0.5% Triton X-5 
100. Immunostaining was performed using anti-PHEX  (1:500; Abcam; ab96072), anti-Na-K-ATPase 6 
(1:100; 610992, BD Bioscience) or anti-calnexin (1:100; 610523, BD Bioscience) antibodies; and 7 
using secondary anti-mouse AlexaFluor-488 and anti-rabbit AlexaFluor-594 antibodies (Invitrogen). 8 
Cells were visualised using a Zeiss fluorescent microscope. Colocalisation quantification was 9 
performed using BioimageX (23). The percentage of PHEX immunostaining at the plasma membrane 10 
or ER was quantified using a minimum of six slides from at least four separate experiments, and 11 
compared between WT and mutant-expressing cells using the Student’s t-test. 12 
 13 
 14 
 15 
4. Results 16 
 17 
DNA sequence analysis of the PHEX coding regions and adjacent splice sites identified a novel 18 
heterozygous G-to-T transversion at nucleotide c.2158 in exon 22 in the patient (Fig. 1C). This G-to-T 19 
transversion (GCA to TCA) resulted in a missense substitution, p.Ala720Ser, of the PHEX protein 20 
(Fig. 1D). The absence of this DNA sequence abnormality in >6500 exomes from the EVS cohort and 21 
>60,700 exomes from the ExAC cohort, together with evolutionary conservation of the Ala720 22 
residue in vertebrate PHEX orthologs (Figure 1E), indicated that the Ala720Ser abnormality likely 23 
represented a pathogenic PHEX mutation rather than a benign polymorphic variant. No alterations in 24 
PHEX gene dosage or in the PHEX 3’UTR were identified. Moreover, analysis of the DMP1, ENPP, 25 
FGF23 and SLC34A3 genes, which are involved in phosphate homeostasis and have been associated 26 
with FGF23-mediated hypophosphatemia (1, 18), did not reveal any abnormalities. 27 
PHEX proteins that harbor missense mutations have previously been shown to be sequestered 28 
intracellularly (3), and we therefore investigated whether the Ala720Ser mutation may impair the 29 
expression and cellular processing of PHEX by in vitro transient transfection of WT (Ala720) or 30 
 8 
mutant (Ser720) PHEX full-length cDNA constructs in HEK293 cells. Western blot analysis of whole 1 
cell lysates obtained from transfected HEK293 cells demonstrated similar levels of expression of WT 2 
and mutant PHEX proteins, whereas, cells transfected with an empty vector (control) were shown to 3 
not express PHEX (Fig. 2A). Immunofluorescence analysis of permeabilised and non-permeabilised 4 
cells was undertaken to determine the cellular localization of WT and mutant PHEX proteins (Fig. 5 
2B-C). A localisation analysis of non-permeabilised cells revealed that ~80% of the total cellular 6 
amount of WT PHEX was localised at the plasma membrane (Fig. 2B and 2D). Whereas, in 7 
permeabilised cells, less than 20% of WT PHEX was localised in the ER (Figure 2C-D). In contrast, 8 
only ~20% of the mutant Ser720 PHEX protein was localised at the plasma membrane in non-9 
permeabilised cells (Fig. 2B and 2D), whereas greater than 60% of mutant PHEX was associated with 10 
the ER (Fig. 2C-D). These findings indicate impaired trafficking and ER retention of the mutant 11 
Ser720 PHEX protein. 12 
 13 
5. Discussion 14 
 15 
Our studies have identified a pathogenic PHEX mutation in a patient with elevated circulating FGF23 16 
concentrations and hypophosphatemic osteomalacia that first manifested in adulthood. Although, 17 
PHEX mutations are occasionally detected in osteomalacic adults (24), and even in asymptomatic 18 
adults (25), such cases usually arise within a kindred known to be affected with XLH. In contrast, the 19 
patient reported here did not have a known family history of rickets or osteomalacia, which indicates 20 
that her adult-onset XLH had likely occurred sporadically. It is of note that this patient was also 21 
diagnosed with PsA, which is an inflammatory musculoskeletal disease characterised by features such 22 
as arthritis, dactylitis, psoriatic skin disease and nail dystrophy (26). Moreover, PsA has been 23 
associated with elevated serum FGF23 concentrations (27), and this may potentially have contributed 24 
to the FGF23 excess in this patient. Furthermore, she was found to have enthesopathic changes on 25 
plain radiography. Such findings have been reported in >65% of XLH patients (28) and in 30-50% of 26 
PsA patients (26), and thus the cause of the enthesopathy in this patient who is affected with both of 27 
these conditions, remains to be elucidated. In addition, she had a history of dental abscesses that 28 
 9 
began in childhood and were attributed to prior trauma, but which may potentially have represented 1 
an early manifestation of XLH. Indeed, dental abscesses are a common feature of XLH in children 2 
and have been reported to affect the primary dentition of 25% of XLH patients (29). 3 
 The missense Ala720Ser mutation identified in this case involved the substitution of a WT 4 
non-polar alanine residue with a mutant polar serine residue, and this was predicted to result in 5 
misfolding and retention of the mutant PHEX protein within the ER (3). Indeed, >50% of XLH-6 
causing missense PHEX mutations, which includes another mutation affecting codon 720 of the 7 
PHEX gene (Ala720Thr), have previously been shown to impair trafficking of the mutant PHEX 8 
protein to the plasma membrane (3). Our in vitro studies revealed the Ala720Ser mutation to partially 9 
abrogate cell surface expression of the PHEX protein, and these milder pathogenic effects may 10 
explain why the patient became symptomatic only in adulthood. Another contributing factor to the 11 
milder clinical phenotype may have been cellular mosaicism arising from skewed X-inactivation of 12 
the mutant PHEX gene (30). Although it should be noted that such skewing has not been reported in 13 
peripheral blood cells obtained from females with XLH (31), and it remains to be elucidated whether 14 
preferential inactivation of the mutant PHEX gene may occur in FGF23-secreting cells such as 15 
osteocytes. Some females with XLH have been reported to have an absence of skeletal disease, and 16 
the only manifestation may be asymptomatic hypophosphatemia (25). Similarly, a recent study of 17 
XLH caused by a PHEX 3’-UTR mutation included an assessment of the affected mothers, and their 18 
only consistent phenotype was a mild reduction in TmP/GFR, which was not associated with 19 
substantial hypophosphatemia or skeletal abnormalities (9). The findings of these previous studies and 20 
the present report highlight that PHEX mutations in females may not present until adulthood or could 21 
potentially go unnoticed throughout adult life (9, 25). 22 
The present case illustrates the challenge of investigating hypophosphatemic patients with 23 
demonstrable FGF23 excess in the absence of a known family history of rickets or osteomalacia. Such 24 
patients are usually suspected of harboring an acquired disorder such as TIO (18), and may undergo 25 
radiological investigations over several years to detect the underlying tumor (14, 32). However, 26 
despite these imaging studies, the causative tumor has been reported to not be identified in 25-60% of 27 
patients with FGF23-mediated adult-onset hypophosphatemic osteomalacia (12, 14, 33), thus 28 
 10 
indicating that some patients may harbor an alternate etiology for their mineral disorder. Our findings 1 
highlight that a monogenic cause of FGF23 excess should be considered in such cases, even in the 2 
absence of a relevant family history, and that PHEX gene analysis may have utility in the 3 
investigation of patients with suspected TIO, particularly when the underlying tumor has not been 4 
identified. Appropriate diagnosis in such cases will prevent unnecessary radiological investigations, 5 
although treatment with phosphate and active vitamin D may not fully alleviate symptoms. Whether 6 
anti-FGF23 antibody treatment (34) would be beneficial in such patients remains to be investigated.  7 
 8 
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Figure legends 1 
 2 
Figure 1.  Clinical findings and PHEX mutational analysis. (A) Pelvic and proximal femoral 3 
radiographs showing bilateral cortical lucencies of the proximal medial femoral diaphysis with 4 
associated focal cortical thickening (yellow arrows), representing an insufficiency-type fracture or 5 
“Looser zone”. Mild enthesopathic changes affecting the ischial tuberosities (red arrowheads) and an 6 
incidental finding of L5 spina bifida (black arrow) are also noted. (B) Graphs showing serum 7 
concentrations of phosphate (Pi), alkaline phosphatase (ALP) and fibroblast growth factor-23 8 
(FGF23) over an 8-year period. Boxes above graphs indicate periods of treatment with ergocalciferol 9 
(D2), and with oral phosphate and alfacalcidol. (C) DNA sequence analysis showing a heterozygous 10 
G-to-T transversion at nucleotide c.2158 (red arrow) of the PHEX gene. (D) This sequence 11 
abnormality was predicted to lead to a missense amino acid substitution of Ala to Ser at codon 720. 12 
(E) Multiple protein sequence alignment of PHEX orthologs. The WT Ala720 (A) residues are shown 13 
in black, and the mutant Ser720 (S) residue is shown in red. Conserved residues are shaded grey. 14 
 15 
Figure 2. Cellular localization of WT and mutant PHEX. (A) Western blot showing elevated levels of 16 
PHEX protein following transfection of HEK293 cells with a vector encoding WT or mutant PHEX 17 
as compared to cells transfected with an empty vector. (B) Immunofluorescence of non-permeabilised 18 
HEK293 cells showing the co-localisation of PHEX (red) with Na-K-ATPase, which is a plasma 19 
membrane-associated protein (green). (C) Immunofluorescence of permeabilised HEK293 cells 20 
showing the co-localisation of PHEX (red) with calnexin, which is an ER-associated protein (green). 21 
(D) Quantification of co-localisation of WT or mutant PHEX protein with plasma membrane or ER-22 
associated proteins in HEK293 cells. *p<0.05; bars show standard deviation.  23 
  24 
 14 
Table 1. Serum biochemical parameters at presentation. 1 
 2 
Parameter 
 
Value Reference range 
Sodium (mmol/L) 136 135-145 
Potassium (mmol/L) 3.7 3.5-5.0 
Creatinine (μmol/L) 57 54-145 
Albumin-adjusted calcium (mmol/L) 2.41 2.20-2.60 
Phosphate (mmol/L) 0.43 0.70-1.40 
Alkaline phosphatase (U/L) 136 30-130 
Urate (μmol/L) 237 140-360 
Parathyroid hormone (pmol/L) 11 1.1-6.9 
25-hydroxyvitamin D (nmol/L) 72.4 Adequate >50 
1,25-dihydroxyvitamin D (pmol/L) 98 43-144 
FGF23 (RU/mL) 779 <100 
 3 
  4 
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